uniQure (Nasdaq: QURE) has been a public company since 2014.

We thank our investors for their support as we advance our gene therapy pipeline toward commercialization.
Contact us at any time.

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease modifying therapies to patients with severe disorders.

We are leveraging our modular and validated technology platform to rapidly advance a focused pipeline of gene therapies.

Stock Quote

Recent News

Upcoming Events

March 6-8, 2017
Cowen & Co. Global Healthcare Conference, Boston, MA
Presentation: Wednesday March 8th, 10.00 a.m. EST

March 21-22, 2017
Oppenheimer's 27th Annual Healthcare Conference, New York City 
Presentation: Tuesday March 21st, 3.55 p.m. EST

April 4-5, 2017
Deutsche Biotechnologie Tage, Hannover, GE

April 19-23, 2017
EASL - The International Liver Congress, Amsterdam, NL